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Objectives
My goals for you at the end this lecture:
❖
❖
❖
❖

Comfort in determining which transgender patients meet criteria for
initiating CSH
Appreciation of the overlap between transgender identity and psychiatric
disease as mediated primarily by trauma
Improved self efficacy in weighing risks/benefits of CSH therapy
Familiarity with resources available to help support primary care
providers take care of transgender patients

Transgender Community Size
❖
❖
❖

0.1-0.5% of global population1,2
Estimated at 700,000 US persons3
Isolated global examples exist:
➢
➢

Fa’afafines (Samoa)
Hijra (India)

1.Bye L, Gruskin E, Greenwood, G, Albright V, Krotki K. California Lesbians, Gays, Bisexuals, and Transgender (LGBT) Tobacco Use Survey – 2004. Sacramento, CA: California Department of Health Services, 2005.
2.Conron K, Scott G, Stowell G, Landers S. Transgender Health in Massachusetts: Results From a Household Probability Sample of Adults. Am J Public Health. 2012 January; 102(1): 118–122.
3.Gates GJ. How Many People Are Lesbian, Gay, Bisexual, and Transgender? Los Angeles, CA: Williams Institute, University of California, Los Angeles School of Law; 2011. Available at: http://www3.law.ucla.edu/ williamsinstitute/pdf/How-many-people-are-LGBTFinal.pdf. Accessed
November 2015.

The Trans Community and Healthcare
❖

Only 30-40% of transgender persons receive regular medical care4

❖

19% had been refused medical care5

❖

28% verbally harassed in medical setting5

❖

2% physically assaulted in a physician’s office5

❖

50% have had to teach their physician about transgender health5

❖

Barriers: inability to access transgender friendly, and
transgender-knowledgeable physicians4

4.Sanchez NF, Sanchez JP, Danoff A. Health Care Utilization, Barriers to Care, and Hormone Usage Among Male-to-Female Transgender Persons in New York City. American Journal of Public Health. 2009;99(4):713-719.
5 Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M. Injustice at Every Turn: A Report of the National Transgender Discrimination Survey. Washington: National Center for Transgender Equality and National Gay and Lesbian Task Force, 2011
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Cases 1 & 2
D.H., a 22 y.o biological female seeking CSH
●
●
●
●
●

●

Transidentity emerged in 9th grade
“I am in the wrong body”
Wanted to be on the baseball team
instead of softball team
Hates being penetrated during sex b/c
reminder “that I have a vagina”
Transitioned socially 2 years prior, has
undergone legal name change, uses male
pronouns in all aspects of life
Has been seeing a gender therapist for 2
years, hx of adjustment disorder, no
other chronic psych/medical dx

A.D., a 34 y.o. biological male seeking CSH
●

●
●
●
●
●
●

Since I was a toddler I “always knew I
was not a boy but I did not know of an
alternative”
“At first I thought I was just gay” and
came out as gay to family yrs ago
Came out as trans to sister only 1 week
prior
Hx of drug abuse with multiple
intentional overdoses
Incarcerated (drug related)
Succeeded in getting bachelor’s and
planning to go to law school soon
"I want to start hormones today”

Interviewing Prior to Initiation of CSH therapy
●
●
●
●
●
●
●
●
●
●
●
●

Emergence and persistence of transidentity?
Goals of treatment (appear more masculine/feminine?, Top or bottom surgery?, androgynous
appearance?)
Social Support- Family? Friends? Work colleagues?
Trauma history? (emotional, verbal, physical, sexual abuse)
Psychiatric Hx? (hospitalizations, medications, SI/HI, attempts)
History of prior gender affirming interventions (prescribed vs unprescribed meds, surgeries)?
Employment, Food, Housing issues?
Sexuality, and STD risks
Substance use?
Plans for fertility?
Hx of preventative screenings especially sex organ screenings?
Other medical problems?

Cases 1 & 2
D.H., a 22 y.o biological female seeking HRT
●
●
●
●
●

●

Transidentity emerged in 9th grade
“I am in the wrong body”
Wanted to be on the baseball team
instead of softball team
Hates being penetrated during sex b/c
reminder “that I have a vagina”
Transitioned socially 2 years prior, has
undergone legal name change, uses male
pronouns in all aspects of life
Has been seeing a gender therapist for 2
years, hx of adjustment disorder, no
other chronic psych/medical dx

A.D., a 34 y.o. biological male seeking HRT
●

●
●
●
●
●
●

Since I was a toddler I “always knew I
was not a boy but I did not know of an
alternative”
“At first I thought I was just gay” and
came out as gay to family yrs ago
Came out as trans to sister only 1 week
prior
Hx of drug abuse with multiple
intentional overdoses
Incarcerated (drug related)
Succeeded in getting bachelor’s and
planning to go to law school soon
"I want to start hormones today”

Cross Sex Hormones
❖

Estrogens (and androgen blockers) in people assigned to male sex at birth

❖

Androgens in people assigned to female sex at birth

❖

Purpose: induce/maintain physical and physiological characteristics of sex
that matches a person’s gender identity

❖

Not all trans people will take

❖

Various protocols exist; no head to head trials comparing safety, efficacy

❖

Eg. 50mg once a week subcutaneously of testosterone cypionate

❖

Eg. 2mg BID of estradiol sublingually, and 50mg BID of spironolactone

Selection of Appropriate Adult Patients for CSH
WPATH Standards of Care, 7th Version

Transgender ≠ Gender Dysphoria

Criteria for Hormone Therapy
1.
2.
3.
4.

6

Persistent, well-documented gender dysphoria
Capacity to make a fully informed decision and to consent to treatment
Age of majority in a given country*
If significant medical or mental health concerns are present, they must be
reasonably well controlled

Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People 7th version. The World Professional Association for Transgender
Health. 2011 <http://www.wpath.org>

Cases 1 & 2
D.H., a 22 y.o biological female seeking HRT
●
●
●
●
●

●

Transidentity emerged in 9th grade
“I am in the wrong body”
Wanted to be on the baseball team
instead of softball team
Hates being penetrated during sex b/c
reminds him “that I have a vagina”
Transitioned socially 2 years prior, has
undergone legal name change, uses male
pronouns in all aspects of life
Has been seeing a gender therapist for 2
years, hx of adjustment disorder, no
other chronic psych/medical dx

A.D., a 34 y.o. biological male seeking HRT
●

●
●
●
●
●
●

Since I was a toddler I “always knew I
was not a boy” but did not know of an
alternative
At first thought “I was just gay” and
came out to family yrs ago
Came out as trans to sister only 1 week
prior
Hx of drug abuse with multiple
intentional overdoses
Incarcerated (drug related)
Succeeded in B.S. and planning to go to
law school
"I want to start hormones today”

Case 1 Continued
D.H. was started on typical dose of testosterone cypionate (50mg SQ qweek)
1 month later seen in f/u and patient reports:
❖
❖
❖

“Change in voice”
“Increased energy”
“Slight increase in facial hair”

Requesting increase in testosterone dose to accelerate changes.

❖
❖
❖

7

Changes take years to be complete
Some changes are reversible,
others are permanent
Early, intermediate, late changes

Taken from Cavanaugh, T, Hopwood, R, Gonzalez, A, Thompson, J. The medical care of transgender persons. Boston, MA: Fenway Health; 2015 Oct. 38 p.

7

Taken from Cavanaugh, T, Hopwood, R, Gonzalez, A, Thompson, J. The medical care of transgender persons. Boston, MA: Fenway Health; 2015 Oct. 38 p.

❖
❖
❖
❖

❖

7

Changes take years to be complete
Some changes are reversible,
others are permanent
Goal is to achieve physiologic range
of hormones
Checking hormones can be
particularly helpful if patient is not
masculinizing/feminizing along
expected time course
Avoid supraphysiologic levels of
hormones

Taken from Cavanaugh, T, Hopwood, R, Gonzalez, A, Thompson, J. The medical care of transgender persons. Boston, MA: Fenway Health; 2015 Oct. 38 p.

Cases 1&2 Summary
❖

Taking a transgender history

❖

Criteria exist to help you determine patient appropriateness for CSH
therapy

❖

Hormonal transition is a process that can take 2-3 years (or longer) to be
complete
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Case 3
D.D., a 26 yo transgender male with psych hx of bipolar (stable for years)
❖
❖
❖
❖

11/11/2016 - RN does patient teaching on self administration of T
11/15/2016 - pap smear visit
11/27/2016 - E.D. visit for increased anxiety, ran out of meds
11/30/2016 - clinic follow up
➢
➢
➢

❖

New onset sexual interest & activity
Notified therapist
Agreed to closely follow

12/8/2016- hospitalized for acute mania

Mental Health & Transpersons
❖

The majority of transgender population does not have a clinically
coexisting psychiatric condition!!!

❖

Still, transpersons at high risk for mood disorders, thought to be socially
induced by transphobia (prejudice against transgender persons)

Transphobia

Barriers to employment,
education
Isolation/Rejection

Chronic
Stress/Traumas

Substance Abuse
Psychiatric Distress
Suicide Risk

Impact of CSH on Mental Health
❖ Some evidence that access to gender affirming therapies can improve the
quality of life and psychiatric symptomatology in transgender patients

8.

➢

Better self esteem, mood after access to hormone therapy8

➢

Lower rates of self reported anxiety and depression9

➢

CSH associated with improved QoL and mental health but level of evidence low10

Gomez-Gil E, Zubiaurre-Elorza L, Esteva I, et al; Hormone-treated transsexuals report less social distress, anxiety, and depression. Psychoneuroendocrinology 2012; 37:
662-670.
9.
Colizzi M, Costa E, Todarello O.Transsexual patients' psychiatric comorbidity and positive effect of cross sex hormonal treatment on mental health: results from a
longitudinal study. Psychoneuroendocrinology 2014; 39: 65-73.
10.
White Hughto JM, Reisner SL. A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals.
Transgender Health 2016; 1(1): 21-31.

Mental Health & Access to Gender Affirming Treatment
❖

Relief of gender dysphoria

Transphobia

Barriers to employment,
education
Isolation/Rejection

Chronic
Stress/Traumas

Substance Abuse
Psychiatric Disease
Suicide Risk

What about testosterone?
❖

No clear evidence that testosterone
precipitates mania
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Case 4
M.D. is a 50 year old transgender woman with HTN and tbx dependence and
with new onset of right lower extremity symptoms concerning for intermittent
claudication. She has been on a regimen of 3mg BID of oral estradiol for many
years. As part of her workup, she underwent a treadmill ABI, the results of
which are significant for moderate to severe arterial occlusive disease of the
bilateral lower extremities. Concerned, MD inquires whether this diagnosis
requires her to stop taking estradiol.

Some Potential Side Effects of Estrogen Therapy
❖

Elevated blood pressure

❖

Decreased glucose tolerance

❖

Weight gain

❖

Increased triglycerides

Hormones, CVD risks in Transwomen
❖

Degree of cardiovascular risk posed by oral estrogen remains
controversial

❖

Subsequent studies of cisgender women contradictory conclusions about
the risk of stroke and MI in postmenopausal women on HRT11

❖

Some evidence that transwomen on estrogen > CVD mortality than
cismales12

❖

But, higher rates of smoking, HLD in transwomen compared to cisgender
males confound evidence

❖

High quality RCTs on transwomen lacking

Route of Estrogen & CVD risk
❖

Switching from oral to a transdermal form of estrogen delivery may
present a lower risk option

❖

Studies in cisgender postmenopausal women that found no association of
stroke with low doses of transdermal estrogen as compared with the
elevated stroke risk seen with both low and high doses of oral
estrogen13,14

❖

Unclear- may involve differential activation of the coagulation and/or
inflammatory cascades?

Case 4 Conclusion
❖

Started on a regimen of aspirin 81mg, atorvastatin 40mg

❖

Referred to vascular surgery for further management

❖

Behavioral counseling for smoking cessation and daily exercise

❖

Switched to transdermal estrogen for continuation of her cross sex
hormone therapy
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Resources
❖

❖

❖

❖

UCSF Center of Excellence for Transgender Health
➢ Guidelines for the Primary and Gender-Affirming Care of Transgender and
Gender Nonbinary People, 2nd edition, July 2016
➢ http://transhealth.ucsf.edu/trans?page=guidelines-home
Fenway Institute
➢ The Medical Care of Transgender Persons, Fall 2015
➢ http://fenwayhealth.org/
Transline
➢ Free online medical consultation service
➢ http://project-health.org/transline/
National Center for Transgender Equality
➢ www. transequality.org
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Thank you!

DSM-V
Gender Dysphoria in Adolescents and Adults
1.

2.

A marked incongruence between one’s experienced/expressed gender and assigned gender, of at least 6 months’ duration, as
manifested by at least two of the following:
1.
A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex
characteristics (or in young adolescents, the anticipated secondary sex characteristics).
2.
A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with
one’s experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated
secondary sex characteristics).
3.
A strong desire for the primary and/or secondary sex characteristics of the other gender.
4.
A strong desire to be of the other gender (or some alternative gender different from one’s assigned gender).
5.
A strong desire to be treated as the other gender (or some alternative gender different from one’s assigned gender).
6.
A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender
different from one’s assigned gender).
The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of
functioning.

"Gender Dysphoria." American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington: American Psychiatric Association, 2013.

